Analysis identifies tumor characteristics affecting outcomes in stage II non-small cell lung cancer, suggesting tailored adjuvant therapy strategies.
Tumor size, nodal involvement, and histologic subtype are key prognostic determinants in stage II NSCLC. Identifying high-risk patients is crucial to optimize selection for adjuvant immunotherapy or targeted therapy and to ensure clinical and economic benefit.
No takes yet. Share an insight, caveat, or question.
SHEN et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: